Morgan Stanley Downgrades Teva Pharma (TEVA) to Equalweight
Tweet
Share
E-mail
Get Alerts TEVA Hot Sheet
Price: $37.62 --0%
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 4 | New: 3
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 4 | New: 3
Join SI Premium – FREE
Morgan Stanley downgraded Teva Pharma (NYSE: TEVA) from Overweight to Equalweight with a price target of $42.00 (from $63.00).
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $37.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
- Equitable Group (EQB:CN) (EQGPF) PT Raised to Cdn$146 at RBC Capital
- Nagoya Railroad (9048:JP) PT Raised to JPY1,950 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
